Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019
May 16 2019 - 5:00AM
Heidelberg, Germany, May 16, 2019 – Affimed N.V.
(Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that it will host a conference call on
Wednesday, May 22, 2019 at 8:30 a.m. ET to discuss its first
quarter 2019 financial results and recent corporate
developments.
The conference call will be available via phone
and webcast. To access the call, please dial +1 631 510 7495 for
U.S. callers, or +44 (0) 2071 928000 for international callers, and
reference conference ID 1083705 approximately 15 minutes prior to
the call.
An audio webcast of the conference call can be
accessed in the “Webcasts” section on the “Investors” page of the
Affimed website at https://www.affimed.com/investors/webcasts/. A
replay of the webcast will be available on Affimed’s website
shortly after the conclusion of the call and will be archived for
30 days following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company that engineers targeted immunotherapies,
seeking to improve patient outcomes through the power of innate
immunity. Affimed’s fit-for-purpose ROCK® platform allows innate
immune engagers to be designed for specific patient populations.
The Company is developing single and combination therapies to treat
cancers. For more information, please visit www.affimed.com.
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024